ライフサイエンスコーパス: bronchiolitis

1 idelines for the diagnosis and management of bronchiolitis.

2 asopharyngeal microbiota and the severity of bronchiolitis.

3 e conducted for 2 years after the episode of bronchiolitis.

4 guidelines advise against pharmacotherapy in bronchiolitis.

5 ple of healthy infants hospitalized with RSV bronchiolitis.

6 among infants with a first episode of acute bronchiolitis.

7 eroid use in infants with a first episode of bronchiolitis.

8 udy of infants (age <1 yr) hospitalized with bronchiolitis.

9 respiratory outcomes of infants with severe bronchiolitis.

10 biome profiles, and severity in infants with bronchiolitis.

11 f airway microbiota and CCL5 in infants with bronchiolitis.

12 ght the role of LL-37 in the pathogenesis of bronchiolitis.

13 s with COPD with emphysema that is absent in bronchiolitis.

14 s were associated with decreased severity in bronchiolitis.

15 ergency department with a diagnosis of acute bronchiolitis.

16 e patient was suspected to have eosinophilic bronchiolitis.

17 t associated with a poor clinical outcome in bronchiolitis.

18 severity of airflow limitation of those with bronchiolitis.

19 to decrease LOS in infants hospitalized with bronchiolitis.

20 use of acute lower respiratory infection and bronchiolitis.

21 two major causes of pediatric pneumonia and bronchiolitis.

22 for infants admitted to hospital with viral bronchiolitis.

23 f 2615 enrolled children, 1764 (67%) had RSV bronchiolitis.

24 ce suggests clinical heterogeneity within RV bronchiolitis.

25 mic load are at a higher risk of more-severe bronchiolitis.

26 nomic load had a higher risk for more-severe bronchiolitis.

27 y disease (OAD), a correlate of obliterative bronchiolitis.

28 nd nasal swabs from infants hospitalized for bronchiolitis.

29 ntinuous pulse oximetry use in children with bronchiolitis.

30 ciated with acute and chronic morbidities of bronchiolitis.

31 hrough pathways other than acute severity of bronchiolitis.

32 high-risk group of infants hospitalized for bronchiolitis.

33 agnosis was bronchial asthma associated with bronchiolitis.

34 lome and both the microbiota and severity of bronchiolitis.

35 ne samples collected from infants with acute bronchiolitis.

36 eded to optimise and unify the management of bronchiolitis.

37 host systemic response, and pathobiology of bronchiolitis.

38 ntilation (PPV), in infants hospitalized for bronchiolitis.

39 We observed that in emphysema (but not in bronchiolitis) (1) up-regulated genes were enriched in o

40 Two grade 3 AEs were reported (both bronchiolitis; 1 JNJ-8678, 1 placebo), reported as serio

41 hile 30%-70% of RSV-infected infants develop bronchiolitis, 2% require hospitalization.

42 921 infants (age <1 year) hospitalized with bronchiolitis (2011-2014 winters) with posthospitalizati

43 alization rates by census tract quintile for bronchiolitis (32.8, 20.8, 14.0, 10.4, and 5.1 per 1000)

44 ratory infection, croup, asthma, bronchitis, bronchiolitis, a wheezy lower respiratory infection or f

45 for Scotland was used to extract data on all bronchiolitis admissions (International Classification o

46 s study aimed to describe temporal trends in bronchiolitis admissions for children under 2 years of a

47 cal trials, understanding national trends in bronchiolitis admissions is an important proxy for deter

48 y epithelium play a key role in constrictive bronchiolitis after lung transplantation, the typical ha

49 interleukin 10 (IL-10) were elevated in RSV+ bronchiolitis (all P < .05), furthermore CCL5 and IL-10

50 pitalizations per 1000 children per year for bronchiolitis and 1.6 (range across census tracts, 0-4.3

51 spiratory symptoms found to have lymphocytic bronchiolitis and alveolar ductitis with B-cell follicle

52 able strategy to limit the severity of viral bronchiolitis and break its nexus with asthma.

53 nger than 2 years who were hospitalized with bronchiolitis and children younger than 18 years who wer

54 roll children aged <2 years hospitalized for bronchiolitis and collect nasopharyngeal aspirates.

55 erential expression and gene coexpression in bronchiolitis and emphysema.

56 irus (RSV) is the leading cause of pediatric bronchiolitis and hospitalizations.

57 nza virus (PIV) in humans is associated with bronchiolitis and pneumonia and can be especially proble

58 Bronchiolitis and pneumonia are leading causes of pediat

59 burden, treatment options for RSV-associated bronchiolitis and pneumonia are limited and mainly consi

60 We calculated bronchiolitis and pneumonia hospitalization rates for Ha

61 Bronchiolitis and pneumonia hospitalization rates varied

62 he respiratory tract and is a major cause of bronchiolitis and pneumonia in children and the elderly.

63 ) are two closely related viruses that cause bronchiolitis and pneumonia in infants and the elderly(1

64 3) are major viral agents of acute pediatric bronchiolitis and pneumonia worldwide that lack vaccines

65 cute respiratory infection (ARI), especially bronchiolitis and pneumonia, in children worldwide.

66 virus (RSV) is a leading cause of childhood bronchiolitis and pneumonia, particularly in early infan

67 RSV) is the most frequent cause of infantile bronchiolitis and pneumonia.

68 into novel therapeutic approaches for viral bronchiolitis and pneumonia.

69 eased infiltration of the virus, lymphocytic bronchiolitis and reduced survival of Pgam5 (-/-) mice.

70 In this study, we induced obliterative bronchiolitis and studied the contribution of regulatory

71 reg cell expansion to protect against severe bronchiolitis and subsequent asthma.

72 viable future therapy for severe RSV-induced bronchiolitis and thereby prevent the inception of subse

73 re associated with disease severity in acute bronchiolitis and to evaluate whether detected viruses m

74 ion of serum LL-37 levels to the severity of bronchiolitis and viral etiology.

75 sRAGE) with acute and chronic morbidities of bronchiolitis and whether the effect of serum sRAGE on d

76 caused by a combination of airways disease (bronchiolitis) and parenchymal destruction (emphysema),

77 y 39% (95% CI 5-62) for all-cause pneumonia, bronchiolitis, and asthma admissions in children aged 2-

78 r/infrequent wheeze, maternal asthma, infant bronchiolitis, and atopic dermatitis were associated wit

79 virus (HRV) is a major cause of common cold, bronchiolitis, and exacerbations of chronic pulmonary di

80 mphocytic interstitial pneumonia, follicular bronchiolitis, and light-chain deposition disease are in

81 n, presenting with symptoms including croup, bronchiolitis, and pneumonia.

82 luding acute cellular rejection, lymphocytic bronchiolitis, and Pseudomonas isolation after transplan

83 associated with higher risk of pneumonia and bronchiolitis, and this increased risk was likewise decr

84 classic respiratory syncytial virus-induced bronchiolitis; and profile C (36%), which was composed o

85 s, acute cellular rejection, and lymphocytic bronchiolitis are associated with an increased risk of D

86 with rhinovirus (RV) infection-particularly bronchiolitis-are at high risk for developing childhood

87 tions, 18 (24%) had an unscheduled visit for bronchiolitis as compared with 11 of the 43 infants with

88 e of ineffective medications in infants with bronchiolitis at discharge from emergency departments is

89 lobal variation in prescribing practices for bronchiolitis at discharge from emergency departments.

90 or inhaled corticosteroids) for infants with bronchiolitis at discharge from emergency departments.

91 Five studies carried out after bronchiolitis at less than 24 months of age, with a foll

92 ively followed 166 children hospitalized for bronchiolitis at less than 6 months of age until 5-7 yea

93 After bronchiolitis at less than 6 months of age, the risk of

94 s are hypersusceptible to severe/acute viral bronchiolitis (AVB), for reasons incompletely understood

95 monary edema in severe cases to constrictive bronchiolitis, being a more distant consequence.

96 s (aged <12 months) who were discharged with bronchiolitis between Jan 1 and Dec 31, 2013 from 38 eme

97 ion was defined as a diagnosis of pneumonia, bronchiolitis, bronchitis, or bronchial hyperreactivity.

98 diagnosis (HR=1.23; 95% CI: 0.97, 1.55) and bronchiolitis/bronchitis (HR=1.13; 95% CI: 0.99, 1.30).

99 l A pregnancy level and increased asthma and bronchiolitis/bronchitis rates in childhood were consist

100 of infants (aged < 1 year) hospitalized for bronchiolitis, by using routinely-available pre-hospital

101 ofiling of urine specimens from infants with bronchiolitis can be used to identify children at increa

102 here is definitive evidence that RSV-induced bronchiolitis can damage the airways to promote airway o

103 As data have shown bronchiolitis cannot simply be diagnosed using a certain

104 espiratory syncytial virus caused 66% of the bronchiolitis cases, and nearly half of the patients wer

105 With the majority of bronchiolitis caused by respiratory syncytial virus (RSV

106 Rationale: Respiratory syncytial virus (RSV) bronchiolitis causes significant infant mortality.

107 Bronchiolitis causes substantial disease in young childr

108 a) respiratory syncytial virus (RSV)-induced bronchiolitis, characterized by young age of the patient

109 Although bronchiolitis contributes to substantial acute (e.g., in

110 ns similar to those typical for obliterative bronchiolitis developed in vivo after reconstitution wit

111 Current data indicate that the "bronchiolitis" diagnosis comprises more than one conditi

112 try monitoring of nonhypoxemic patients with bronchiolitis did not shorten hospital length of stay an

113 y tree and can cause tracheitis, bronchitis, bronchiolitis, diffuse alveolar damage with pulmonary ed

114 In infants hospitalized with acute bronchiolitis, disease severity was not associated with

115 rosolized particles produced by infants with bronchiolitis due to RSV was measured using viable impac

116 1005 infants (age <1 year) hospitalized for bronchiolitis during 2011-2014, we observed statisticall

117 V) is a leading cause of viral pneumonia and bronchiolitis during the first six months of life.

118 n 2 years of age or younger hospitalized for bronchiolitis during the period from 2009 to 2014 at 1 o

119 lower respiratory illness (ie, pneumonia or bronchiolitis) during ages 12-24 months per additional G

120 ng evidence suggesting that the diagnosis of bronchiolitis encompasses several diseases with distinct

121 We aimed to identify RV bronchiolitis endotypes and examine their longitudinal r

122 alysis identified biologically meaningful RV bronchiolitis endotypes in infants, such as one characte

123 etwork and clustering approaches to identify bronchiolitis endotypes.

124 The majority of infants with mild bronchiolitis experienced recurrent or sustained desatur

125 Acute bronchiolitis frequently causes infant hospitalization.

126 as the number of episodes with pneumonia and bronchiolitis from 0 to 3 years of age.

127 tation, and disease severity in infants with bronchiolitis from RSV subtypes and new RSV genotypes.

128 icacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE) study was a multicenter, double

129 6 of 557 infants (19%) hospitalized with RSV bronchiolitis had the same RSV subtype 3 weeks later (ie

130 hospital length of stay (LOS) in acute viral bronchiolitis have suggested benefit.

131 A better understanding of bronchiolitis heterogeneity might help clarify its relat

132 of Moraxella or Streptococcus species after bronchiolitis hospitalization was associated with recurr

133 of RSV hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH) before and after 201

134 There were 1495 bronchiolitis hospitalizations and 1231 pneumonia hospit

135 s were collected from 363 infants with acute bronchiolitis in a randomized, controlled trial that com

136 nfants less than 1 year old hospitalized for bronchiolitis in an Italian university hospital over 12

137 irus (RSV) is a major cause of pneumonia and bronchiolitis in children.

138 of age of children who were hospitalized for bronchiolitis in early infancy.

139 ovirus infection alone predisposed to severe bronchiolitis in early life and subsequent asthma in lat

140 the risk of childhood asthma, pneumonia, and bronchiolitis in genetically susceptible subjects.

141 Respiratory syncytial virus (RSV) bronchiolitis in infancy is a major risk factor for recu

142 V) is the most common cause of serious viral bronchiolitis in infants, young children, and the elderl

143 Infant respiratory syncytial virus (RSV) bronchiolitis in the first 6 months of life was associat

144 Infant RSV bronchiolitis in the first six months of life was associ

145 It appears that the first episode of severe bronchiolitis in under 2-year-old children is a critical

146 rways of pediatric patients with RSV-induced bronchiolitis in vast numbers: approximately 80% of infi

147 etapneumovirus (hMPV) is a frequent cause of bronchiolitis in young children.

148 tial virus (RSV) is the most common cause of bronchiolitis in young infants.

149 y outcome was unscheduled medical visits for bronchiolitis, including a visit to any health care prof

150 Clinical severity of bronchiolitis increased in 2016-2017 and 2017-2018 and c

151 ospital admission for asthma, bronchitis and bronchiolitis (International Classification of Diseases,

152 pital admissions for asthma, bronchitis, and bronchiolitis (International Classification of Diseases,

153 Viral bronchiolitis is a common clinical syndrome affecting in

154 Respiratory syncytial virus-bronchiolitis is a major independent risk factor for sub

155 Bronchiolitis is associated with a greater risk of devel

156 of neutrophils in patients with RSV-induced bronchiolitis is best performed under the umbrella of an

157 Bronchiolitis is characterized by airway epithelial cell

158 tial virus (RSV) in infants hospitalized for bronchiolitis is not known.

159 Bronchiolitis is the commonest cause of respiratory rela

160 Bronchiolitis is the leading cause of hospital admission

161 Acute bronchiolitis is the leading cause of hospitalization am

162 RATIONALE: Bronchiolitis is the most common lower respiratory infec

163 ection [AR]) or peribronchiolar (lymphocytic bronchiolitis [LB]) distribution, is common in lung tran

164 lticenter study of infants hospitalized with bronchiolitis, lower levels of serum LL-37 were associat

165 s may reflect the evolving evidence base for bronchiolitis management, and platforms should be create

166 course in infants hospitalized for acute RSV bronchiolitis may depend on the RSV genotype.

167 Of 122 infants hospitalized for RV bronchiolitis (median age, 4 months), we identified 4 di

168 In 886 infants with bronchiolitis, median age was 2.9 months.

169 In 140 infants with bronchiolitis, metabolomic profiling was performed on se

170 philic airway inflammation in a murine viral bronchiolitis model, demonstration of similar effects in

171 hose born in the 3 months preceding the peak bronchiolitis month-September, October, and November.

172 In children with viral bronchiolitis, nasal propionate levels were decreased an

173 to 12 months of age with physician-diagnosed bronchiolitis newly admitted into eight paediatric hospi

174 he first time that infants with RSV-positive bronchiolitis nursed in a ward setting or ventilated in

175 Obliterative bronchiolitis (OB) is a clinical syndrome marked by prog

176 ansplant survival is limited by obliterative bronchiolitis (OB), but the mechanisms of OB development

177 brosis in lung and skin leads to progressive bronchiolitis obliterans (BO) and scleroderma, respectiv

178 Given the impact of T cells on bronchiolitis obliterans (BO) in lung transplantation, w

179 g-term outcome of lung transplantation, with bronchiolitis obliterans (BO) representing the predomina

180 a proposed mechanism driving posttransplant bronchiolitis obliterans (BO), and its clinical correlat

181 ultiorgan system disease model that includes bronchiolitis obliterans (BO), dependent upon GC B cells

182 chronic GVHD in a multiorgan system model of bronchiolitis obliterans (BO), driven by germinal center

183 use of the associations between diacetyl and bronchiolitis obliterans and other severe respiratory di

184 mouse model of multiorgan system injury with bronchiolitis obliterans associated with a robust GC rea

185 thelial and intraluminal fibrotic lesions of bronchiolitis obliterans by day 28.

186 Therefore, earlier bronchiolitis obliterans detection and more timely imple

187 osttransplantation course was complicated by bronchiolitis obliterans from chronic rejection and by r

188 s were identified to show histopathology for bronchiolitis obliterans in all allogeneic grafts.

189 Bronchiolitis obliterans is the leading cause of chronic

190 antly elevated within 3 months of developing bronchiolitis obliterans syndrome (8.3 [1.4-25.1] vs. 3.

191 with human cytomegalovirus increases risk of bronchiolitis obliterans syndrome (aHR, 2.88; 95% CI, 1.

192 In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic

193 emic steroids are the standard treatment for bronchiolitis obliterans syndrome (BOS) after allogeneic

194 Bronchiolitis obliterans syndrome (BOS) after lung trans

195 after lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients

196 lowing lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients

197 allograft dysfunction (CLAD), presenting as bronchiolitis obliterans syndrome (BOS) or restrictive a

198 ll lung transplant recipients suffering from bronchiolitis obliterans syndrome (BOS) or restrictive a

199 n (AR) and development of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major lim

200 ween these disorders and risk for subsequent bronchiolitis obliterans syndrome (BOS), mortality and g

201 Bronchiolitis obliterans syndrome (BOS), the major cause

202 irreversible decline in lung function termed bronchiolitis obliterans syndrome (BOS).

203 The primary endpoint was freedom from bronchiolitis obliterans syndrome (BOS).

204 obliterans (BO), and its clinical correlate bronchiolitis obliterans syndrome (BOS).

205 The per-protocol analysis shows incidence of bronchiolitis obliterans syndrome (BOS): 1/43 in the Eve

206 rvival (P = 0.09) and increased freedom from bronchiolitis obliterans syndrome (P = 0.03) was observe

207 enting chronic rejection of lung allografts (bronchiolitis obliterans syndrome [BOS]) and proinflamma

208 Different clinical phenotypes (bronchiolitis obliterans syndrome [BOS]-neutrophilic BOS

209 smatch model of multiorgan system cGVHD with bronchiolitis obliterans syndrome and a minor MHC mismat

210 Because current literature suggests bronchiolitis obliterans syndrome and restrictive allogr

211 rom lung transplant recipients who developed bronchiolitis obliterans syndrome and were compared to s

212 condary end points were overall survival and bronchiolitis obliterans syndrome at 2 years.

213 survival in a multivariable model including bronchiolitis obliterans syndrome grade and baseline FEV

214 Bronchiolitis obliterans syndrome has been associated wi

215 o activate fibroblasts in the development of bronchiolitis obliterans syndrome has not been evaluated

216 after heart transplantation, and potentially bronchiolitis obliterans syndrome in lung transplant rec

217 Bronchiolitis obliterans syndrome is caused by a fibropr

218 and were divided into three groups: no CLAD (bronchiolitis obliterans syndrome level 0 [BOS 0]), earl

219 onic lung allograft dysfunction manifests as bronchiolitis obliterans syndrome or the recently descri

220 Importantly, the 2014 NIH-CC for bronchiolitis obliterans syndrome perform poorly in chil

221 Bronchiolitis Obliterans Syndrome seriously reduces long

222 Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the a

223 s that CMVIG prophylaxis reduces the risk of bronchiolitis obliterans syndrome, but a controlled tria

224 Among lung transplant recipients, "bronchiolitis obliterans syndrome," a disorder with clin

225 nd 30-day mortality, follow-up survival, and bronchiolitis obliterans syndrome-free survival.

226 lantation imitate the in vivo development of bronchiolitis obliterans syndrome-like lesions and revea

227 reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.

228 defined as idiopathic pneumonia syndrome or bronchiolitis obliterans syndrome.

229 ociated with an increased risk of developing bronchiolitis obliterans syndrome.

230 hromycin, and montelukast should be used for bronchiolitis obliterans syndrome; and the addition of n

231 ted rejection, acute cellular rejection, and bronchiolitis obliterans syndrome; however, the signific

232 rgan system, nonsclerodermatous disease with bronchiolitis obliterans where cGVHD is dependent on ant

233 arget tissue that results in scleroderma and bronchiolitis obliterans, diagnostic features of cGVHD.

234 WT APC normalized bronchiolitis obliterans-induced pulmonary dysfunction.

235 after ECP in lung allograft recipients with bronchiolitis obliterans.

236 ure is small airway obstruction arising from bronchiolitis obliterans.

237 ssue fibrosis manifesting as scleroderma and bronchiolitis obliterans.

238 and pulmonary dysfunction characteristic of bronchiolitis obliterans.

239 ces epithelial injury via TGF-beta in murine bronchiolitis obliterans; that TGF-beta and the C' casca

240 ght paediatric hospital units in the UK (the Bronchiolitis of Infancy Discharge Study [BIDS]).

241 lt mice, pDC depletion predisposed to severe bronchiolitis only after antibiotic treatment.

242 ntified among children suffering from severe bronchiolitis (or first wheezing episode): (a) respirato

243 reactive airways disease, BPD exacerbation, bronchiolitis, or pneumonia, or a respiratory-related ho

244 ve cohort study in infants hospitalized with bronchiolitis over 3 winters (2011-2014).

245 inical severity in infants hospitalized with bronchiolitis over 6 epidemic seasons (2012-2013 to 2017

246 microbiota plays an important role in viral bronchiolitis pathobiology.

247 rmine whether necroptosis contributes to RSV bronchiolitis pathogenesis via HMGB1 (high mobility grou

248 osed asthma was present in 13% of the former bronchiolitis patients at 11-13 years of age.

249 te, trachea, lungs, and intestine with acute bronchiolitis present in infected lungs.

250 Severe bronchiolitis profiles at baseline (hospitalization) wer

251 We sought to identify severe bronchiolitis profiles using a clustering approach and t

252 Three severe bronchiolitis profiles were identified: profile A (15%),

253 naging infants and children hospitalized for bronchiolitis recommend only obtaining intermittent or "

254 and very young, with some infants developing bronchiolitis, recurrent wheezing, and asthma following

255 cept study azithromycin treatment during RSV bronchiolitis reduced upper airway IL-8 levels, prolonge

256 te whether azithromycin treatment during RSV bronchiolitis reduces serum and nasal lavage IL-8 levels

257 mine the relation of the nasal microbiota at bronchiolitis-related hospitalization and 3 later points

258 n, acute cellular rejection, and lymphocytic bronchiolitis remained independent risk factors for DSA

259 omized clinical trials of HS in infants with bronchiolitis reporting LOS as an outcome measure were i

260 and radiologically determined bronchiectasis/bronchiolitis, respectively, and 5.21 (1.50, 18.07; p=0.

261 independent populations of infants with RSV bronchiolitis revealed that the severity of RSV infectio

262 Among 774 infants with severe bronchiolitis, rhinovirus species related to distinct na

263 -37 levels and the most common virus causing bronchiolitis, RSV.

264 ively enrolled term infants hospitalized for bronchiolitis, samples positive for RSV A ON1 (N = 139)

265 rial on 2 parallel groups conducted during 2 bronchiolitis seasons (October through March) from Octob

266 hods are flawed, particularly in a pediatric bronchiolitis setting.

267 Serum metabolome profiles differed by bronchiolitis severity (P < .001).

268 etabolome profiles significantly differed by bronchiolitis severity (P < 0.001).

269 ate the potential of metabolomics to predict bronchiolitis severity and better understand microbe-hos

270 ines significantly associated with decreased bronchiolitis severity are classified in a wide range of

271 achine learning models to accurately predict bronchiolitis severity, and to compare their predictive

272 ciations of the upper-airway microbiome with bronchiolitis severity, little is known about the mechan

273 lp identify, among children hospitalized for bronchiolitis, subgroups with particularly increased ris

274 Moreover, during RTIs, including viral bronchiolitis, the local microbiome appears to play an i

275 Among 842 infants hospitalized for bronchiolitis, there was 88% follow-up at 3 years, and 3

276 Management of infants with bronchiolitis to an oxygen saturation target of 90% or h

277 is, four as sarcoidosis, four as respiratory bronchiolitis, two as organising pneumonia, and 18 as su

278 ive cohort study of infants hospitalized for bronchiolitis was analyzed.

279 Severity of bronchiolitis was defined by intensive care use and hosp

280 of infants (age <12 months) hospitalized for bronchiolitis, we integrated clinical, RV species (RV-A,

281 rgency department with signs and symptoms of bronchiolitis were eligible for enrollment.

282 t at University Hospital of Padova for acute bronchiolitis were enrolled (77% tested positive for res

283 One hundred eleven children with bronchiolitis were enrolled.

284 Twenty-four infants with bronchiolitis were recruited: 12 were respiratory syncyt

285 ined RSV in the air surrounding infants with bronchiolitis were sufficiently small to remain airborne

286 l virus (RSV) is the main causative agent of bronchiolitis, whereas rhinovirus (RV) is most commonly

287 n oxygen saturation of 90% for children with bronchiolitis, which is consistent with the WHO recommen

288 alysis can be used to identify children with bronchiolitis who are at risk of developing recurrent wh

289 try monitoring in hospitalized children with bronchiolitis who do not require supplemental oxygen.

290 ent of infants and children hospitalized for bronchiolitis who show clinical improvement.

291 a first episode of acute moderate to severe bronchiolitis who were admitted to the pediatric ED rela

292 patients aged 8 weeks through 23 months with bronchiolitis who were not receiving active supplemental

293 enience sample of children hospitalized with bronchiolitis who were not receiving active supplemental

294 erwise healthy infants hospitalized with RSV bronchiolitis who were treated with azithromycin or plac

295 wever, it remains unclear which infants with bronchiolitis will develop severe illness.

296 it is impossible to know which infants with bronchiolitis will develop this condition.

297 inclusion, 777 with a first episode of acute bronchiolitis with respiratory distress and no chronic m

298 ations for the pharmacological management of bronchiolitis, with conflicting recommendations over whe

299 emergency department or hospitalisations for bronchiolitis within 21 days of discharge.

300 Hospitalization with bronchiolitis without active supplemental oxygen adminis